Scarica l'app Stockscreener
243.14
3.51%
8.25
Pre-mercato:
242.78
-0.36
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$234.89
Aprire:
$233.66
Volume 24 ore:
10.17M
Relative Volume:
1.64
Capitalizzazione di mercato:
$429.58B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
119.93
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
+12.31%
1M Prestazione:
+12.72%
6M Prestazione:
+5.76%
1 anno Prestazione:
+31.15%
Intervallo 1D:
$233.66
$244.61
Intervallo di 1 settimana:
$221.94
$244.61
Portata 52W:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
243.14 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,127.69 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
244.88 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
125.45 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.12 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (DUS:4AB0) - TradingView
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix? - Yahoo Finance
Enterprise value to EBITDA forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
A Look at AbbVie Inc (ABBV) After 3.5% Gain -- GF Value $211.36 vs Price $243.14 - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Price to book forward of AbbVie, Inc. – TURQUOISE:4ABD - TradingView
Enterprise value to EBIT forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie Inc Stock (ABBV) Moved Up by 3.22% on Jun 25: Drivers Behind the Movement - TradingKey
Is AbbVie a Buy After Its Purchase of Apogee? - aol.com
AbbVie to acquire Apogee Therapeutics in $10.9 billion immunology deal - DOTmed
Pharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bet - Pharmaceutical Commerce
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook - Yahoo Finance
The Number That Could Test AbbVie Stock - Trefis
AbbVie's Big Immunology Acquisition - Forbes
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years - Benzinga
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis - Zacks Investment Research
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $260 to $298 - Moomoo
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal - Yahoo Finance
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com Canada
PRESCRIPTION DRUGS—W.D. Wash.: Novartis, AbbVie, PhRMA denied preliminary relief in challenge to Washington State 340B delivery law - VitalLaw.com
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors. - Yahoo Finance
Here's How Much You'd Need to Invest in HDV to Generate $500 per Month in Dividends - The Motley Fool
ABBV Reiterated by Piper Sandler -- Price Target Maintained at $298 - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds - PR Newswire
CCORF Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $273 - Moomoo
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout - Yahoo Finance
Abbvie stock holds at Market Perform as Bernstein eyes Apogee deal - Investing.com Canada
ABBV Introduces Boey for Glabellar Lines Following Health Canada Approval - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $234 to $298 - Moomoo
AbbVie receives European approval for age three patients - grafa.com
Years of Rewards: $61 Bil From AbbVie Stock - Trefis
Canaccord raises Abbvie stock price target on acquisition potential - Investing.com
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) - Yahoo Finance
Canaccord raises Abbvie stock price target on acquisition potential By Investing.com - Investing.com Canada
Should You Buy Or Sell AbbVie Stock At $230? - Yahoo Finance
Possible Bearish Signals With AbbVie Insiders Disposing Stock - Moomoo
AbbVie Stock Rose 6% After Its $11 Billion Apogee Deal: What a $347 Target Means for Investors - TIKR.com
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Canada clears Boey, a fast-acting neurotoxin that fades in 2-3 weeks - Stock Titan
AbbVie receives European approval for age six patients - grafa.com
AbbVie (ABBV) Gains European Approval for Skyrizi in Younger Pat - GuruFocus
ABBV Receives EU Approval for Maviret Treatment - GuruFocus
AbbVie (ABBV) Secures EU Approval for Skyrizi in Pediatric Psori - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace
AbbVie (ABBV) Gains European Approval for SKYRIZI in Pediatric P - GuruFocus
AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection - Investing News Network
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):